Scholarlink

Purpose <p>Prolactinomas are often treated initially with dopamine agonists (DA). For patients subsequently treated with surgery, the effect of cabergoline (CAB) on tumor fibrosis and its potential impact on surgical outcomes is largely unexplored.</p> Methods <p>Records of patients with prolactinoma treated by a single surgeon between 2006 and 2024 were examined. Analyses considered relationships among duration and cumulative dose of presurgical DA (DA + vs. DA-), extent of fibrosis measured quantitatively by collagen volume fraction (CVF) and qualitatively by surgeon assessment, and remission status at last follow-up.</p> Results <p>Of 59 patients, 22 were DA- and 37 were DA+, including 29 treated only with CAB and 8 treated with CAB and bromocriptine. There were 44 macroadenomas, 13 microadenomas, and 2 giant adenomas; 28 had cavernous sinus invasion (Knosp grade 3–4) 52.5% were in remission at last follow-up. Median cumulative CAB dose was 79.3&#xa0;mg (range, 5.4–6711), used for a median duration of 570 days (range, 16-7830). Neither CAB dose nor duration correlated with CVF (r<sup>2</sup> &lt; 0.01, p = NS). Both surgeon fibrosis assessment and CVF were higher in DA + patients, but neither independently predicted remission. Cumulative CAB dose and duration also did not predict remission. On univariable analysis, cavernous sinus invasion (OR 10.3, <i>p</i> &lt; 0.001) and tumor size (OR 6.6, <i>p</i> = 0.02) predicted remission, but in multivariable analysis no single factor remained significant.</p> Conclusion <p>Duration and cumulative dose of presurgical CAB use do not correlate with quantitative measures of tumor fibrosis and do not reliably predict the degree of fibrosis at surgery or the likelihood of surgical remission.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月12日

查看全文
  • Adam N. Mamelak,
  • Rachel Fox,
  • Yaakov Rosenberg,
  • Daniel Gomez,
  • Yujie Cui,
  • Anat Ben-Shlomo,
  • Artak Labadzhyan,
  • Ning-Ai Liu,
  • Vivien Bonert,
  • Odelia Cooper

摘要

Purpose

Prolactinomas are often treated initially with dopamine agonists (DA). For patients subsequently treated with surgery, the effect of cabergoline (CAB) on tumor fibrosis and its potential impact on surgical outcomes is largely unexplored.

Methods

Records of patients with prolactinoma treated by a single surgeon between 2006 and 2024 were examined. Analyses considered relationships among duration and cumulative dose of presurgical DA (DA + vs. DA-), extent of fibrosis measured quantitatively by collagen volume fraction (CVF) and qualitatively by surgeon assessment, and remission status at last follow-up.

Results

Of 59 patients, 22 were DA- and 37 were DA+, including 29 treated only with CAB and 8 treated with CAB and bromocriptine. There were 44 macroadenomas, 13 microadenomas, and 2 giant adenomas; 28 had cavernous sinus invasion (Knosp grade 3–4) 52.5% were in remission at last follow-up. Median cumulative CAB dose was 79.3 mg (range, 5.4–6711), used for a median duration of 570 days (range, 16-7830). Neither CAB dose nor duration correlated with CVF (r2 < 0.01, p = NS). Both surgeon fibrosis assessment and CVF were higher in DA + patients, but neither independently predicted remission. Cumulative CAB dose and duration also did not predict remission. On univariable analysis, cavernous sinus invasion (OR 10.3, p < 0.001) and tumor size (OR 6.6, p = 0.02) predicted remission, but in multivariable analysis no single factor remained significant.

Conclusion

Duration and cumulative dose of presurgical CAB use do not correlate with quantitative measures of tumor fibrosis and do not reliably predict the degree of fibrosis at surgery or the likelihood of surgical remission.